ReviewNeurochemical research2025
Deficient Astrocyte Homeostatic Support Contributes to Brain Impairment in Duchenne Muscular Dystrophy.
Review in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to their muscle functions, dystrophins -the protein products of the DMD gene - also play a role in the central nervous system (CNS). In Duchenne muscular dystrophy (DMD), the progressive muscle degeneration, is associated with cognitive and behavioural impairments, which are severe in one-third of patients and substantially increase the overall clinical burden. The mechanisms of these neuropsychiatric abnormalities are complex and only partially understood. Specific dystrophins are functionally important in various brain cells and at their specialisations, with further diversity occurring throughout brain development and maturation across brain regions. Mutations affecting the full-length dystrophins (Dp427) cause the disease, while the additional loss of shorter isoforms (Dp140 and Dp71) can exacerbate the clinical presentation. Truncated dystrophins are strongly expressed in the healthy brain and therefore were investigated extensively, but most of DMD patients presenting with neuropsychiatric abnormalities do not have mutations affecting these isoforms. When the full-length dystrophins are considered, the abnormalities unquestionably involve not only neurones but also astrocytes, where absence of dystrophins reduces proliferation, disrupts neurotransmitter regulation, synaptic stability, and neurovascular integrity. Deficiency of astrocytic dystrophins impairs glutamate clearance, leading to excitotoxicity and neuronal hyperexcitability linked to multiple neuropsychiatric manifestations. This review evaluates evidence on dystrophin's role in astrocytes, its contribution to synaptic malfunction, and parallels with other neurodevelopmental disorders. Understanding that the deficient astrocyte homeostasis contributes to DMD can lead to the exploration of novel therapeutic strategies involving astrocyte-mediated neurotransmitter regulation to mitigate neuropsychiatric deficits.
Indexed as
Identifiers
40571876What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.